Trial Review

The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial registered on ANZCTR


Registration number
ACTRN12615000319572
Ethics application status
Approved
Date submitted
24/03/2015
Date registered
9/04/2015
Date last updated
30/07/2019
Date data sharing statement initially provided
26/11/2018
Type of registration
Prospectively registered

Titles & IDs
Public title
Does sildenafil reduce the risk of fetal distress in labour?
Scientific title
Investigating if Sildenafil Citrate (50mg PO 8hrly) administration in labour reduces the rates of emergency operative delivery for fetal distress and improves fetal and uteroplacental blood flow on Dopper ultrasound in term (37-42 weeks), singleton, appropriately grown pregnancies
Secondary ID [1] 286327 0
Nil
Universal Trial Number (UTN)
U1111-1167-5821
Trial acronym
RIDSTRESS
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Intrapartum fetal hypoxia 294432 0
Condition category
Condition code
Reproductive Health and Childbirth 294738 294738 0 0
Normal pregnancy
Reproductive Health and Childbirth 294739 294739 0 0
Fetal medicine and complications of pregnancy

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Participants will be randomised to either placebo orally 8 hourly (maximum three doses in 24 hours) or sildenafil citrate 50mg orally 8 hourly (maximum 150mg in 24 hours).

Only women at term (37-42 weeks of pregnancy) are eligible. Participants will be randomised when delivery is anticipated within 72 hours and dosing regimen commenced when transferred to birth suite for management of labour. Doses will be administered intrapartum in labour ward by medical and midwifery staff under supervision and unused drug tablets will be returned and disposed of in adherence with hospital policy.
Intervention code [1] 291374 0
Treatment: Drugs
Intervention code [2] 291540 0
Prevention
Comparator / control treatment
placebo (capsulated, no active ingredients) taken orally 8 hourly for up to three doses maximum in 24 hours.
Control group
Placebo

Outcomes
Primary outcome [1] 294499 0
To ascertain if the use of sildenafil citrate in labour is associated with a reduction in the incidence of intrapartum fetal compromise requiring emergency delivery. For the purposes of this study emergency delivery is defined as either caesarean section or instrumental vaginal delivery where the primary indication for delivery is concern for fetal wellbeing (non-reassuring fetal status).
Timepoint [1] 294499 0
Until delivery of the baby.
Primary outcome [2] 294500 0
To ascertain if sildenafil is associated with improved fetal and uteroplacental blood flow on Doppler ultrasound
Timepoint [2] 294500 0
Within four hours of first dose of sildenafil citrate/placebo
Secondary outcome [1] 313463 0
To ascertain if sildenafil is associated with an improvement in neonatal outcomes as defined by a composite neonatal outcome score (admission to neonatal intensive care unit, APGAR <7 at 5 minutes, cord pH<7.1 or lactate >6mmol/L, neonatal encephalopathy).
Timepoint [1] 313463 0
To neonatal discharge from hospital
Secondary outcome [2] 313465 0
To ascertain if sildenafil citrate is associated with a reduction in intrapartum fetal heart rate abnormalities (as demonstrated and interpreted from cardiotocograph) or meconium stained liquor.
Timepoint [2] 313465 0
Until delivery of the baby.
Secondary outcome [3] 313883 0
To ascertain if sildenafil citrate is associated with a reduction in the need for intrapartum fetal blood sampling. This data is collected from the clinical notes where performance of fetal blood sampling is documented.
Timepoint [3] 313883 0
Until delivery of the baby.
Secondary outcome [4] 354374 0
To establish the extent to which sildenafil citrate crosses the placenta into the fetal circulation by measuring umbilical cord blood levels of sildenafil citrate or its active metabolite (N-Desmethyl-Sildenafil). Plasma samples will be sent to the BioNotus GCV laboratory in Belgium for assay.
Timepoint [4] 354374 0
From time of delivery to within 2 hours of birth. This window is the timeframe in which cord blood can be obtained. Samples will be immediately sent to the local hospital laboratory to be processed and stored at -80degrees Celsius prior to all samples being sent to the laboratory in Belgium for SC assay at the end of the study period for batch processing.

Eligibility
Key inclusion criteria
*Aged between 18-50 who are able to give informed consent
*Singleton pregnancy at 37-42 weeks gestation
*Appropriately grown fetus without any structural, chromosomal or genetic abnormality.
*Admitted in spontaneous labour (cervical dilatation <4cm) or prior to induction of labour
*Planning a vaginal delivery
Minimum age
18 Years
Maximum age
50 Years
Sex
Females
Can healthy volunteers participate?
Yes
Key exclusion criteria
*Women <18 years old
*Those unable to give informed consent
*Women with pre-existing heart disorders, stroke, hypotension or hypertension, retinitis pigmentosa, kidney or liver abnormalities, sickle cell anaemia, stomach ulcers or any other bleeding disorder.
*Women on any anti-hypertensive medication.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Pregnant women at term (37-42 weeks) will be recruited from the Pregnancy Assessment and Observation Unit, Antenatal clinic or Antenatal Wards at the Mater Mothers’ Hospital, Raymond Terrace, Brisbane, QLD, Australia.
Women with singleton pregnancies who are admitted in early labour (<4cm dilated) with regular uterine contractions OR women prior to induction of labour will be approached to participate in this study. The aim is to recruit women who have had apparently “normal” low risk pregnancies who will deliver within 72 hours of recruitment.
Participants will be given the Participant Information sheet and encouraged to ask question. Participants will then be required to sign a consent form.
Information about the maternal age, ethnicity, parity, booking blood pressure, gestation at onset of labour, body mass index, history of smoking, pre-existing maternal medical disorders, history of previous fetal growth restriction, stillbirth or neonatal death will be recorded on a pro-forma sheet.
At recruitment, all participants will have an ultrasound scan to measured fetal biparietal diameter, head circumference, abdominal circumference and femur length thereby allowing an estimated fetal weight to be calculated. Doppler assessment of several fetal vessels and cardiac function as well as maternal uterine Doppler indices and vessel diameters (Pulsatility index, Resistance index and maximum velocity) will be recorded. The amniotic fluid index will also be measured. The entire ultrasound assessment should not take longer than 30-40 mins. In addition these women will have a blood sample (10ml) taken for measurement of placental growth factor (PlGF) levels.
After the ultrasound, the participant will be computer randomised to either Sildenafil or placebo. The first dose of sildenafil or placebo will be administered when the woman is transferred to the Birth Suite for management of labour. The dose of Sildenafil will be 50mg taken orally every 8 hours for a maximum of 24 hours (total dose 150mg. ie 3 doses only). Both the active drug and the placebo will be provided by the Pharmacy department at the Mater Mothers’ Hospital in sealed opaque envelopes in sequential order of computer generated randomisation. Allocation will be concealed. Following the first dose of either Sildenafil or placebo a repeat ultrasound scan will be performed within 2-4 hours to assess fetal cardiac function and blood flow in various fetal vessels (umbilical artery, middle cerebral artery and ductus venosus) as well as the maternal uterine arteries. The second scan should not take longer than 20 mins to perform.
Clinicians managing the pregnancy will be blinded as to the results of the ultrasound scan and the blood tests to ensure that the care these women receive is not influenced by the results. After delivery, case notes for all participants will be reviewed, and intra-partum and neonatal outcomes collected.
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Simple randomisation using a randomisation table created by computer software (i.e. computerised sequence generation).
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 2
Type of endpoint/s
Efficacy
Statistical methods / analysis
This is a double blinded, randomised controlled trial (Phase II trial). The sample size calculation was based on our previous data which showed that the incidence of emergency operative delivery (caesarean section or instrumental vaginal delivery) for fetal compromise was approximately 18.9%. If sildenafil was successful in halving the rate of caesarean section in this cohort to 9.5%, a total sample size of 288 women per group (>90% power, alpha of 0.05) would be required. Assuming a 10% drop out rate, a sample of 320 women per group should be sufficient to adequately address the research objectives.

Recruitment
Recruitment status
Completed
Date of first participant enrolment
Anticipated
1/06/2015
Actual
29/09/2015
Date of last participant enrolment
Anticipated
1/01/2019
Actual
3/01/2019
Date of last data collection
Anticipated
Actual
21/02/2019
Sample size
Target
640
Accrual to date
Final
300
Recruitment in Australia
Recruitment state(s)
QLD
Recruitment hospital [1] 3547 0
Mater Mother's Hospital - South Brisbane
Recruitment postcode(s) [1] 9348 0
4101 - South Brisbane

Funding & Sponsors
Funding source category [1] 290896 0
Charities/Societies/Foundations
Name [1] 290896 0
Mater Research Translating Research Into Practice (TRIP)
Country [1] 290896 0
Australia
Primary sponsor type
Hospital
Name
Mater Health Service
Address
Aubigny Place
Raymond Tce
South Brisbane QLD 4101
Country
Australia
Secondary sponsor category [1] 289713 0
Individual
Name [1] 289713 0
Prof Sailesh Kumar
Address [1] 289713 0
Mater Medical Research Institute (MMRI)
Aubigny Place
Raymond Tce
South Brisbane QLD 4101
Country [1] 289713 0
Australia

Ethics approval
Ethics application status
Approved
Ethics committee name [1] 292498 0
Mater Health Services Human Research Ethics Committee
Ethics committee address [1] 292498 0
Ethics committee country [1] 292498 0
Australia
Date submitted for ethics approval [1] 292498 0
13/03/2015
Approval date [1] 292498 0
21/05/2015
Ethics approval number [1] 292498 0
15/MHS/33

Summary
Brief summary
Trial website
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 55286 0
Prof Sailesh Kumar
Address 55286 0
Mater Medical Research Institute (MMRI)
Aubigny Place
Raymond Terrace
South Brisbane, QLD, 4101
Country 55286 0
Australia
Phone 55286 0
+61731638111
Fax 55286 0
Email 55286 0
[email protected]
Contact person for public queries
Name 55287 0
Sailesh Kumar
Address 55287 0
Mater Medical Research Institute (MMRI)
Aubigny Place
Raymond Terrace
South Brisbane, QLD, 4101
Country 55287 0
Australia
Phone 55287 0
+61731638111
Fax 55287 0
Email 55287 0
[email protected]
Contact person for scientific queries
Name 55288 0
Sailesh Kumar
Address 55288 0
Mater Medical Research Institute (MMRI)
Aubigny Place
Raymond Terrace
South Brisbane, QLD, 4101
Country 55288 0
Australia
Phone 55288 0
+61731638111
Fax 55288 0
Email 55288 0
[email protected]

Data sharing statement
Will individual participant data (IPD) for this trial be available (including data dictionaries)?
Yes
What data in particular will be shared?
All of the de-identified individual participant data collected during the trial will be made available to other researchers
When will data be available (start and end dates)?
All of the de-identified individual participant data collected during the trial will be made available to other researchers beginning 3 months and ending 10 years after article publication. Data will only be made available to researchers who provide research ethics approval and an appropriate research proposal.
Available to whom?
approved researchers, assessed on individual request basis
Available for what types of analyses?
IPD meta-analysis
How or where can data be obtained?
Requests should be directed to Professor Sailesh Kumar ([email protected]).


What supporting documents are/will be available?

Doc. No.TypeCitationLinkEmailOther DetailsAttachment
376Study protocol    368057-(Uploaded-26-07-2019-11-10-41)-Study-related document.docx



Results publications and other study-related documents

Documents added manually
No documents have been uploaded by study researchers.

Documents added automatically
SourceTitleYear of PublicationDOI
EmbaseReducing the risk of fetal distress with sildenafil study (RIDSTRESS): A double-blind randomised control trial.2016https://dx.doi.org/10.1186/s12967-016-0769-0
EmbaseSafety and efficacy of sildenafil citrate to reduce operative birth for intrapartum fetal compromise at term: a phase 2 randomized controlled trial.2020https://dx.doi.org/10.1016/j.ajog.2020.01.025
EmbaseNeurodevelopmental outcomes in infants following intrapartum maternal oral sildenafil citrate treatment.2021https://dx.doi.org/10.1016/j.ajog.2020.10.036
EmbasePBPK-based dose finding for sildenafil in pregnant women for antenatal treatment of congenital diaphragmatic hernia.2023https://dx.doi.org/10.3389/fphar.2023.1068153
N.B. These documents automatically identified may not have been verified by the study sponsor.